Literature DB >> 15115768

GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies.

Leanne M Dibbens1, Hua-Jun Feng, Michaella C Richards, Louise A Harkin, Bree L Hodgson, Darren Scott, Misty Jenkins, Steven Petrou, Grant R Sutherland, Ingrid E Scheffer, Samuel F Berkovic, Robert L Macdonald, John C Mulley.   

Abstract

A major challenge in understanding complex idiopathic generalized epilepsies has been the characterization of their underlying molecular genetic basis. Here, we report that genetic variation within the GABRD gene, which encodes the GABAA receptor delta subunit, affects GABA current amplitude consistent with a model of polygenic susceptibility to epilepsy in humans. We have found a GABRD Glu177Ala variant which is heterozygously associated with generalized epilepsy with febrile seizures plus. We also report an Arg220His allele in GABRD which is present in the general population. Compared with wild-type receptors, alpha1beta2Sdelta GABAA receptors containing delta Glu177Ala or Arg220His have decreased GABAA receptor current amplitudes. As GABAA receptors mediate neuronal inhibition, the reduced receptor current associated with both variants is likely to be associated with increased neuronal excitability. Since delta subunit-containing receptors localize to extra- or peri-synaptic membranes and are thought to be involved in tonic inhibition, our results suggest that alteration of this process may contribute to the common generalized epilepsies. Copyright 2004 Oxford University Press

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115768     DOI: 10.1093/hmg/ddh146

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  97 in total

1.  Dihydropyrimidinone positive modulation of delta-subunit-containing gamma-aminobutyric acid type A receptors, including an epilepsy-linked mutant variant.

Authors:  Ryan W Lewis; John Mabry; Jason G Polisar; Kyle P Eagen; Bruce Ganem; George P Hess
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

2.  Familial clustering of seizure types within the idiopathic generalized epilepsies.

Authors:  M R Winawer; C Marini; B E Grinton; D Rabinowitz; S F Berkovic; I E Scheffer; R Ottman
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

3.  Impact of inhibitory constraint of interneurons on neuronal excitability.

Authors:  Vallent Lee; Jamie Maguire
Journal:  J Neurophysiol       Date:  2013-09-11       Impact factor: 2.714

4.  Another "tonic" in the realm of epilepsy.

Authors:  Istvan Mody
Journal:  Epilepsy Curr       Date:  2004 Nov-Dec       Impact factor: 7.500

5.  Looking for GABA in all the wrong places: the relevance of extrasynaptic GABA(A) receptors to epilepsy.

Authors:  George B Richerson
Journal:  Epilepsy Curr       Date:  2004 Nov-Dec       Impact factor: 7.500

6.  Reticular nucleus-specific changes in alpha3 subunit protein at GABA synapses in genetically epilepsy-prone rats.

Authors:  Xiao-Bo Liu; Jeffrey Coble; Gilles van Luijtelaar; Edward G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-13       Impact factor: 11.205

Review 7.  Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.

Authors:  Hongjie Yuan; Chian-Ming Low; Olivia A Moody; Andrew Jenkins; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

Review 8.  Defects at the crossroads of GABAergic signaling in generalized genetic epilepsies.

Authors:  Jing-Qiong Kang
Journal:  Epilepsy Res       Date:  2017-08-26       Impact factor: 3.045

9.  SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families with generalized epilepsy with febrile seizures plus.

Authors:  Huihui Sun; Yuehua Zhang; Jianmin Liang; Xiaoyan Liu; Xiuwei Ma; Husheng Wu; Keming Xu; Jiong Qin; Yu Qi; Xiru Wu
Journal:  J Hum Genet       Date:  2008-06-20       Impact factor: 3.172

10.  alpha1beta2delta, a silent GABAA receptor: recruitment by tracazolate and neurosteroids.

Authors:  N Zheleznova; A Sedelnikova; D S Weiss
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.